Discontinued — last reported Q2 '25
U.S. Pharmaceutical — Severance and employee-related costs, net
McKesson U.S. Pharmaceutical — Severance and employee-related costs, net increased by 100.0% to $0.00 in Q2 2025 compared to the prior quarter. Over 3 years (FY 2022 to FY 2025), U.S. Pharmaceutical — Severance and employee-related costs, net shows a downward trend with a -37.0% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
Analysis
How to read this metric
An increase suggests active downsizing or organizational restructuring, while a decrease indicates a more stable workforce environment.
Detailed definition
This metric represents the net expenses incurred by the U.S. Pharmaceutical segment related to workforce reductions, inc...
Peer comparison
Commonly reported by peers as part of restructuring or special charges in segment operating results.
mck_segment_u_s_pharmaceutical_severance_and_employee_related_costs_netHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $2.00M | $0.00 | $0.00 | $6.00M | $3.00M | $0.00 | $0.00 | $3.00M | $1.00M | $8.00M | -$6.00M | $7.00M | $0.00 | $1.00M | $1.00M | -$4.00M | $0.00 |
| QoQ Change | — | -100.0% | — | — | -50.0% | -100.0% | — | — | -66.7% | +700.0% | -175.0% | +216.7% | -100.0% | — | +0.0% | -500.0% | +100.0% |
| YoY Change | — | — | — | — | +50.0% | — | — | -50.0% | -66.7% | — | — | +133.3% | -100.0% | -87.5% | +116.7% | -157.1% | — |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is McKesson's u.s. pharmaceutical — severance and employee-related costs, net?
- McKesson (MCK) reported u.s. pharmaceutical — severance and employee-related costs, net of $0.00 in Q2 2025.
- What is the long-term trend for McKesson's u.s. pharmaceutical — severance and employee-related costs, net?
- Over 3 years (2022 to 2025), McKesson's u.s. pharmaceutical — severance and employee-related costs, net has grown at a -37.0% compound annual growth rate (CAGR), from $8.00M to -$2.00M.
- What does u.s. pharmaceutical — severance and employee-related costs, net mean?
- The net cost of employee layoffs and severance packages within the U.S. Pharmaceutical division.